Cytori Reports Q1 2018 Business and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Cytori Therapeutics (CYTX) Misses Q1 EPS by 1c
May 10, 2018 4:28 PM EDTCytori Therapeutics (NASDAQ: CYTX) reported Q1 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $2.74 million.
Q1 2018 operating cash burn was $4.1 million, compared to $4.8 million for Q1 2017.
For earnings history and... More
